Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MASCT in HCC after curative resection
NCT02026362Phase 2Suspended
- Sponsor
- HRYZ Biotech
- Start
- Jul 2013
- Primary completion
- Jul 2017
- Modality
- Whole Cell Cancer Vaccines, Allogeneic CAR-T, TCR-Engineered T Cells
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of MASCT-1 in hepatocellular carcinoma (HCC) (2 arms), sponsored by HRYZ Biotech. Primary endpoints: Number of Participants with tumor recurrence or metastasis at 5 years and Time of tumor recurrence or metastasis at 5 years. Started Jul 2013; status: suspended.
02
Drugs
MASCT-1
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT02026362.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02026362.